Contemporary Grading for Prostate Cancer: Implications for Patient Care ☆
暂无分享,去创建一个
Lars Egevad | Rodolfo Montironi | Mark A Rubin | Daniel W Lin | Theo van der Kwast | Andreas Erbersdobler | M. Rubin | T. H. van der Kwast | L. Egevad | J. Nelson | J. Epstein | M. Amin | R. Montironi | F. Brimo | A. Erbersdobler | D. Lin | Jonathan I Epstein | Joel B Nelson | Fadi Brimo | Mahul Amin | T. Kwast
[1] H. Sandler,et al. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. , 2011, International journal of radiation oncology, biology, physics.
[2] M. Cooperberg,et al. Active surveillance for the management of prostate cancer in a contemporary cohort , 2008, Cancer.
[3] Kevin C Zorn,et al. The Will Rogers phenomenon in urological oncology. , 2008, The Journal of urology.
[4] J. Blasko,et al. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. , 2007, Brachytherapy.
[5] L. Egevad,et al. Implications of the International Society of Urological Pathology modified Gleason grading system. , 2012, Archives of pathology & laboratory medicine.
[6] A. Partin,et al. Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis. , 2010, Urology.
[7] K. Wallner,et al. Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer. , 2011, International journal of radiation oncology, biology, physics.
[8] T. Stamey,et al. Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.
[9] A. Partin,et al. Preoperative characteristics of high‐Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy , 2012, BJU international.
[10] Oliver Sartor,et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. , 2007, The Journal of urology.
[11] H. G. van der Poel,et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. , 2011, European urology.
[12] Alan W Partin,et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.
[13] E. Barret,et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. , 2011, International braz j urol : official journal of the Brazilian Society of Urology.
[14] B. Trock,et al. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. , 2008, Urology.
[15] A. Evans,et al. Prostatic needle biopsies following primary high intensity focused ultrasound (HIFU) therapy for prostatic adenocarcinoma: histopathological features in tumour and non-tumour tissue , 2012, Journal of Clinical Pathology.
[16] S B Malkowicz,et al. Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .
[17] D. Gleason. Classification of prostatic carcinomas. , 1966, Cancer chemotherapy reports.
[18] A W Partin,et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. , 2000, Urology.
[19] J. Epstein,et al. Should each core with prostate cancer be assigned a separate gleason score? , 2003, Human pathology.
[20] J. Epstein,et al. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. , 2008, The Journal of urology.
[21] Steven Piantadosi,et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. , 2003, The Journal of urology.
[22] J. Ciezki,et al. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy. , 2012, International journal of radiation oncology, biology, physics.
[23] M Emberton,et al. Focal therapy in prostate cancer-report from a consensus panel. , 2010, Journal of endourology.
[24] Jeffrey K. Cohen,et al. A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer , 2009, BJU international.
[25] M. Cooperberg,et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. , 2005, The Journal of urology.
[26] P. Humphrey,et al. The Gleason Score of Tumor at the Margin in Radical Prostatectomy is Predictive of Biochemical Recurrence , 2010, The American journal of surgical pathology.
[27] L. Egevad,et al. Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens. , 2008, Analytical and quantitative cytology and histology.
[28] Alan W Partin,et al. Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience , 2011 .
[29] Lars Egevad,et al. A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens. , 2012, European urology.
[30] A. Billis. Percent Gleason grade (4/5) as prognostic factor in prostate cancer diagnosed at transurethral resection. , 2002, International braz j urol : official journal of the Brazilian Society of Urology.
[31] T. H. van der Kwast,et al. Should we replace the Gleason score with the amount of high-grade prostate cancer? , 2007, European urology.
[32] B. Trock,et al. The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐up , 2012, BJU International.
[33] X. Rébillard,et al. High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology , 2008, BJU international.
[34] D. Chan,et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.
[35] C. Pan,et al. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. , 2000, The American journal of surgical pathology.
[36] Y. Inayama,et al. Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens , 2009, BJU international.
[37] J. Epstein,et al. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. , 2008, The Journal of urology.
[38] Y. Yamada,et al. Ten‐year outcomes of high‐dose, intensity‐modulated radiotherapy for localized prostate cancer , 2011, Cancer.
[39] R. Stock,et al. Disease-specific survival following the brachytherapy management of prostate cancer. , 2006, International journal of radiation oncology, biology, physics.
[40] N. Lawrentschuk,et al. Active surveillance for low-risk prostate cancer: an update , 2011, Nature Reviews Urology.
[41] P. Walsh,et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.
[42] Bruce J Trock,et al. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.
[43] P. Unger,et al. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. , 2011, The Journal of urology.
[44] John T. Wei,et al. Multiple prostate cancer cores with different Gleason grades submitted in the same specimen container without specific site designation: should each core be assigned an individual Gleason score? , 2009, Human pathology.
[45] H. Sandler,et al. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. , 2011, International journal of radiation oncology, biology, physics.
[46] L. Egevad,et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.
[47] D. Bostwick,et al. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. , 2001, The Journal of urology.
[48] J. Cuzick,et al. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading , 2007, BJU international.
[49] Jennifer L. Beebe-Dimmer,et al. Prognostic Gleason grade grouping : data based on the modified Gleason scoring system , 2013 .
[50] S. Crouzet,et al. Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. , 2010, European urology.
[51] A. Dal Pra,et al. Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review. , 2010, Current oncology.
[52] Chin-Lee Wu,et al. Impact on the Clinical Outcome of Prostate Cancer by the 2005 International Society of Urological Pathology Modified Gleason Grading System , 2012, The American journal of surgical pathology.
[53] Ximing J. Yang,et al. Grading of Invasive Cribriform Carcinoma on Prostate Needle Biopsy: An Interobserver Study among Experts in Genitourinary Pathology , 2008, The American journal of surgical pathology.
[54] Misop Han,et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.
[55] B. Donnelly,et al. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. , 2008, The Journal of urology.
[56] Liang Cheng,et al. Preoperative prediction of Gleason grade in radical prostatectomy specimens: the influence of different Gleason grades from multiple positive biopsy sites , 2005, Modern Pathology.
[57] B. Delahunt,et al. Gleason scoring: a comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point , 2010, Pathology.
[58] Gleason Df. Classification of prostatic carcinomas. , 1966 .
[59] M. Kattan,et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.
[60] H. Lee,et al. Evaluation of concordance of Gleason score between prostatectomy and biopsies that show more than two different Gleason scores in positive cores. , 2006, Urology.
[61] B. Trock,et al. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. , 2009, The Journal of urology.
[62] A. Renshaw,et al. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. , 2007, JAMA.
[63] M. Kattan,et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. , 2004, The Journal of urology.
[64] K. Hinnen,et al. Predictors in the outcome of 125I brachytherapy as monotherapy for prostate cancer , 2011, Expert review of anticancer therapy.
[65] W. Hellstrom,et al. J Urol , 2014 .
[66] B. Trock,et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011 , 2013, BJU international.
[67] Jing Ma,et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] B. Trock,et al. Erratum: An updated prostate cancer staging nomogram (partin tables) based on cases from 2006 to 2011 (BJU International 111 (22-29)) , 2013 .
[69] P. Spiess,et al. Achieving the ‘bifecta’ using salvage cryotherapy for locally recurrent prostate cancer: analysis of the Cryo On‐Line Data (COLD) Registry data , 2012, BJU international.